memo-inOncology – SPECIAL ISSUE

Find out the latest news from international oncology congresses and stay at the forefront of clinical innovation and advances in lung cancer research.

The memo inOncology Medical education series: keeping oncologists at the forefront of lung cancer research. memo – inOncology Special Issue Preceptorship reports summarise the latest in lung cancer research and treatments to come out of our sponsored Preceptorship meeting series. The Fundamentals of Designing Clinical Trials series arms oncologists with the information they need to plan and conduct an oncology trial.

Latest congress reports

REGISTER

Get a notification for every published memo – inOncology SPECIAL ISSUE. Register below.


    LATEST NEWS

    ASCO LC 2022 Cover

    memo – inOncology SPECIAL ISSUE

    Congress Report ASCO Lung Cancer 2022

    A GLOBAL DIGEST ON APPROACHES IN LUNG CANCER
    Report from the ASCO Congress,

    3rd-7th June 2022

    Now available!

    EHA 2022 cover en

    memo – inHematology SPECIAL ISSUE

    Congress Report EHA 2022

    Report from the European Hematology Association (EHA) Congress,
    9th–12th June 2022

    Now available!

    VIEW ALL OUR REPORTS

    EXPERT VIDEOS

    All videointerviews from EHA 2022

    Naval Daver overviews the most promising new agents in the treatment of AML, how existing drugs can blend into new regimens and how the prognosis of patients with AML will evolve in the years to come. Finally, he talks about risk factors for ICI-related pneumonitis development and if pneumonitis increases mortality in AML patients.

     

    Jorge Castillo explains the most meaningful diagnostic criteria for WM, give insights into the “real-world” treatment of WM with zanubrutinib, bortezomib and other treatment strategies and how to sequence therapies in WM. He explains promising modes of action of new agents in the treatment of WM and depicts his personal highlights from this year’s EHA congress.

    Wojciech Jurczak outlines what can be achieved with the current standard treatments in the setting of follicular lymphoma, which findings have been observed for PI3K inhibitor therapy in the TIDAL study and were we are today with respect to CAR-T cell therapy for patients with follicular lymphoma.

    Constantine Tam highlights the most relevant findings presented at EHA 2022 as well as promising modes of action of new agents in the treatment of indolent lymphomas. He explains how resistance to BTK inhibitors can be addressed in B-cell malignancies while giving an outlook on a BTK protein degrader and finally summarizes the long-term results obtained with zanubrutinib compared to ibrutinib in the ASPEN trial in patients with WM.

    Shirley D’Sa discusses how the treatment and especially the prognosis of patients with WM evolved over the last decades, which approaches can be used to successfully treat patients with MYD88WTWM, how the interaction between WM cells and the bone marrow microenvironment can be used to develop new ways to overcome treatment resistance and finally explains how often the Binge-Neel Syndrome happens, how its diagnosed and how it should be treated.

    EXPERT VIDEOS

    All videointerviews from virtual ESMO Immuno-Oncology 2021

    Mark G. Kris outlines the potential of circulating tumor DNA along the neoadjuvant cancer treatment timeline, explains which correlations have been observed between changes in ctDNA levels and clinical outcomes in patients with early-stage lung cancer and how monitoring of ctDNA can potentially be utilized in clinical practice to guide the management of these patients, while also depicting the limitations of this approach. The excitement in the field of lung cancer about new drugs targeting KRAS in combination with immunotherapy for first line treatment in stage IV NSCLC is addressed, too.

    David McDermott deals with the question if combination therapy is superior to single agent PD-1/PD-L1 blockade in the adjuvant setting, highlights tools/biomarkers for appropriate patient selection for immune checkpoint inhibitor therapies, future strategies to potentially overcome resistance to ICIs, potential new outcome parameters for clinical trials investigating ICIs and highlights the most relevant findings presented at ESMO IO 2021 in terms of immuno-oncology.

    VIEW MEDICAL EDUCATION

    A CONGRESS RESOURCE

    For Oncologists and Hematologists